Insulet’s second quarter delivered notable revenue and profit outperformance, with the company’s results exceeding Wall Street’s expectations and the stock responding with a significant positive move. Management credited the broad-based adoption of Omnipod 5, particularly among new users in both type 1 and type 2 diabetes segments, as well as ongoing international expansion. CEO Ashley McEvoy emphasized, “We grew both year-over-year and sequentially in new customer starts across all of our strategic growth areas: U.S. Type 1, U.S. Type 2, and international.” The integration of new clinical evidence and improved commercial execution were also cited as key contributors to the quarter’s momentum.

Is now the time to buy PODD? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Insulet’s Q2 Earnings Call

• Lilly (JPMorgan) asked about drivers of U.S. and international growth; CEO Ashley McEvoy cited Omnipod 5 adoption, strong clinical outcomes, and commercial execution in both markets.
• Travis Lee Steed (Bank of America) inquired about the sustainability of type 2 diabetes acceleration; McEvoy pointed to robust clinical evidence, expanded pharmacy access, and competitive conversions as ongoing growth drivers.
• Simran (Wells Fargo) questioned U.S. growth variability and longer-term trends; CFO Ana Maria Chadwick explained that normalized growth rates are stable and momentum is expected to continue.
• Joanne Karen Wuensch (Citi Bank) pressed on international expansion; McEvoy described a balanced approach between deepening penetration in core European markets and entering new countries.
• David Harrison Roman (Goldman Sachs) asked about higher capital expenditures; McEvoy and Chadwick clarified that investments are being made to ensure production keeps pace with global demand.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will be tracking (1) the pace of Omnipod 5 adoption in both type 1 and type 2 diabetes segments, (2) progress on international market penetration and customer upgrades from older models, and (3) execution of manufacturing expansion to meet increased demand. The impact of new sensor integrations and evolving reimbursement models will also be closely monitored as potential drivers of future performance.

Insulet currently trades at $306.01, up from $277.32 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.